Abstract：
Polycystic ovary syndrome (PCOS) is a common endocrinopathy worldwide with a heterogeneous clinical presentation including reproductive, metabolic, and endocrine elements. However, the assessment and management of PCOS remains inconsistent, with many women undiagnosed and untreated. We now also understand that the management of PCOS should extend throughout a woman\'s lifespan as many elements of the syndrome persist after menopause. Management has traditionally focused on the treatment of hyperandrogenism and oligomenorrhea. Women with PCOS often have dyslipidemia, hypertension, obesity, and metabolic syndrome, which may be worsened by the hormonal abnormalities, and are therefore at higher risk for cardiovascular disease morbidity and mortality, a risk that increases after menopause. While treatment with hormonal therapy, in particular combined oral contraceptives, may improve cardiovascular risk factors, management plans should incorporate specific diagnosis and management of these factors, if present, because of the strong contribution to the risk for atherosclerotic cardiovascular disease (ASCVD). Given the complexities of the syndrome, optimal management often requires a multi-disciplinary approach including the lipid and cardiometabolic specialist to provide counseling and support for lifestyle modification along with pharmacologic therapy as indicated to address the full range of any reproductive, endocrine, and cardiometabolic abnormalities.
摘要：
多囊卵巢综合征（PCOS）是一种全球常见的内分泌疾病，临床表现包括生殖，新陈代谢，和内分泌元素。然而,对PCOS的评估和管理仍然不一致，许多妇女未经诊断和治疗。我们现在也了解到，PCOS的管理应该贯穿女性的整个生命周期，因为该综合征的许多因素在绝经后仍然存在。传统上，管理侧重于高雄激素血症和月经少发的治疗。PCOS女性常有血脂异常，高血压,肥胖，代谢综合征,荷尔蒙异常可能会恶化，因此心血管疾病发病率和死亡率的风险更高，绝经后风险增加。在用激素疗法治疗时，特别是联合口服避孕药，可以改善心血管危险因素，管理计划应包括对这些因素的具体诊断和管理，如果存在，因为对动脉粥样硬化性心血管疾病（ASCVD）的风险有很大的贡献。鉴于综合症的复杂性，最佳管理通常需要多学科的方法，包括脂质和心脏代谢专家，以提供咨询和支持生活方式的改变以及药物治疗，以解决所有生殖，内分泌，和心脏代谢异常。
